GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Krebs Biochemicals & Industries Ltd-$

Krebs Biochemicals Q2 FY27 Net Loss at (539.85) Rs. In lacs; Vizag Unit Closed

RESULTS ▼ Concern Flagged HIGH RISK
📅 Filed on BSE: 29 Oct 2026, 01:06 PM IST  ·  BSE ID: d082fa95-c8d5-4e35-a756-8382ecd03342
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported a net loss for the quarter, while its main factory remains shut, and a merger is pending approvals.
🤖 AI Summary
  • Krebs Biochemicals & Industries Ltd reported a net loss of (539.85) Rs. In lacs for the quarter ended September 30, 2026.
  • Revenue from operations for Q2 FY27 was 579.03 Rs. In lacs, increasing from 416.74 Rs. In lacs in Q2 FY26.
  • The Vizag manufacturing unit remains closed since February 7, 2025, due to an Andhra Pradesh Pollution Control Board order.
  • The Board approved amalgamation with Ipca Laboratories Limited, with an appointed date of April 1, 2026, subject to approvals.
  • Total expenses for the quarter amounted to 1,122.62 Rs. In lacs, against a total income of 582.77 Rs. In lacs.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from Operations (Q2 FY27)
579.03 Rs. In lacs
Profit / (Loss) for the period (Q2 FY27)
(539.85) Rs. In lacs
Total Expenses (Q2 FY27)
1,122.62 Rs. In lacs
Net Cash Flow from Operating Activities (Half Year FY27)
299.78 Rs. In lacs
🏢 How This Affects the Company
📈
Business Impact
The continued closure of the Vizag manufacturing unit impacts the company's operational capacity and revenue generation, as indicated by the reported revenue from operations of 579.03 Rs. In lacs.
💰
Financial Impact
The company reported a net loss of (539.85) Rs. In lacs for the quarter and accumulated losses of (788.33) Rs. In lacs for the half year, leading to negative 'Other Equity' of (19,219.86) Rs. In lacs.
⚙️
Operational Impact
The ongoing closure of the Vizag unit, ordered on February 7, 2025, signifies a major operational constraint, though the company is engaged in dialogue for revocation.
⚠️
Risk Impact
The continued closure of the Vizag unit poses an ongoing operational and financial risk, as the company operates in one segment only. The pending amalgamation with Ipca Laboratories Limited introduces regulatory approval risk.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the reported net loss of (539.85) Rs. In lacs and negative Basic and Diluted EPS of (2.50) Rs. In Q2 FY27.
🔍
Management Signal
Management continues to address the Vizag unit closure and is pursuing the amalgamation with Ipca Laboratories Limited to restructure the company's future.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Updates on Andhra Pradesh Pollution Control Board order for Vizag unit closure.
Announcements regarding approvals for amalgamation with Ipca Laboratories Limited.
Q3 FY27 financial results to assess ongoing operational and financial trends.
HIGH RISK Ongoing manufacturing unit closure and continued financial losses pose significant operational and solvency risks.
💡 Investor Takeaway
Krebs Biochemicals & Industries Ltd reported a Q2 FY27 net loss of (539.85) Rs. In lacs. Revenue from operations was 579.03 Rs. In lacs. The Vizag manufacturing unit remains closed due to a pollution control board order. Amalgamation with Ipca Laboratories Limited is approved by the Board, pending other necessary consents.
⚖️ Strengths & Concerns

✅ Positives

  • Revenue from operations increased to 579.03 Rs. In lacs in Q2 FY27 from 416.74 Rs. In lacs in Q2 FY26.
  • Net cash flow from operating activities for the half year ended September 30, 2026, was 299.78 Rs. In lacs, up from (167.56) Rs. In lacs in the prior half year.

⚠️ Concerns

  • The company reported a net loss of (539.85) Rs. In lacs for Q2 FY27, reflecting a continued unprofitable operational status.
  • The Vizag manufacturing unit remains closed since February 7, 2025, impacting core operational capacity and revenue potential.
📅 Company Track Record
Krebs Biochemicals & Industries Ltd previously reported a Q1 FY27 net loss of (248.48) Rs. In lacs. The Vizag unit's closure by the Andhra Pradesh Pollution Control Board was first noted in February 2025. The company's board approved amalgamation with Ipca Laboratories on June 26, 2026, with an appointed date of April 1, 2026.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Krebs Biochemicals' net profit or loss in Q2 FY27?
Krebs Biochemicals & Industries Ltd reported a net loss of (539.85) Rs. In lacs for the quarter ended September 30, 2026.
What was Krebs Biochemicals' revenue from operations in Q2 FY27?
Revenue from operations for Krebs Biochemicals & Industries Ltd in Q2 FY27 was 579.03 Rs. In lacs.
Is Krebs Biochemicals' Vizag manufacturing unit currently operational?
No, the operations of Krebs Biochemicals' Vizag manufacturing unit continued to remain closed as of September 30, 2026, pursuant to an order dated February 7, 2025.
What is the status of Krebs Biochemicals' amalgamation with Ipca Laboratories Limited?
The Board of Directors approved the amalgamation of Krebs Biochemicals & Industries Limited with Ipca Laboratories Limited on June 26, 2026, with an appointed date of April 1, 2026, subject to necessary consents and approvals.
What were the total expenses for Krebs Biochemicals in Q2 FY27?
Total expenses for Krebs Biochemicals & Industries Ltd for the quarter ended September 30, 2026, amounted to 1,122.62 Rs. In lacs.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.